Jamie Hartmann-Boyce
Assistant Professor of Health Policy and Management | University of Massachusetts Amherst
Amherst, MA, UNITED STATES
Jamie Hartmann-Boyce's works to synthesize evidence and apply it to health policy, in areas including tobacco control and e-cigarettes.
Expertise (6)
Smoking Cessation
Tobacco Regulatory Science
Health Policy
Tobacco Control
E-cigarettes
Management of Diabetes
Biography
Jamie Hartmann-Boyce joined the UMass Amherst in 2023 after spending 17 years at Oxford University. Her work focuses on health policy, including in the areas of tobacco control, electronic cigarettes, diet, physical activity, and management of long-term chronic conditions.
She is also co-leader the Policy Analysis and Dissemination Core of the Center for the Assessment of Tobacco Regulations (CAsToR) at the University of Michigan, one of seven Tobacco Centers of Regulatory Science (TCORS) funded by the National Institutes of Health and the U.S. Food and Drug Administration.
Video
Publications:
Documents:
Photos:
Videos:
Audio/Podcasts:
Education (3)
University of Oxford: Ph.D., Primary Health Care Sciences
Oxford Brookes University: M.A., History of Medicine
Tufts University: English and Community Health, B.A.
Links (3)
Select Media Coverage (4)
UMass study says e-cigarettes with nicotine can help people quit smoking
MassLive online
2024-01-14
Nicotine-based electronic cigarettes are more effective in curbing smoking habits than typical nicotine replacement therapies, according to a University of Massachusetts Amherst review of health literature.
The Precarious Rise of Disposable Vapes
Wired online
2023-11-18
Jamie Hartmann-Boyce comments in an article on the rise in the use of disposable vapes, especially among young people. “Vaping isn’t 100 percent safe. Some people hear that when you say it’s less harmful than smoking, but I think what people forget is how harmful smoking is,” Hartmann-Boyce says.
There’s a Pill That Helps People Quit Smoking. Why Isn’t It Sold in the U.S.?
Slate online
2023-11-02
UMass Amherst Professor Jamie Hartmann-Boyce discusses a pill that helps people quit smoking but is not available in the U.S. Hartmann-Boyce’s research found that across hundreds of studies, an average of 14% of people who took cystine, a compound found in some seeds, quit smoking for more than six months. This is a far higher number than those who quit using other methods. “We have all this evidence that it works. Shouldn’t we be throwing everything we can at this?” Hartmann-Boyce says.
Nicotine vapes are one of the best tools to help people quit smoking, review of 300 trials suggests
Live Science
2023-09-12
Jamie Hartmann-Boyce's research studied the most effective aids to stop smoking. “Our findings provide clear evidence of the effectiveness of nicotine e-cigarettes and combination nicotine replacement therapies to help people quit smoking,” Hartmann-Boyce says. “The evidence also is clear on the benefits of medicines cytisine and varenicline, but these may be harder for some people to access at the moment.”
Select Publications (3)
E-cigarettes, varenicline and cytisine are the most effective stop-smoking aids, analysis of over 150,000 smokers reveals
CochraneJamie Hartmann-Boyce and others
2023-09-12
A comprehensive new Cochrane analysis has found that nicotine e-cigarettes, varenicline and cytisine are the most effective options currently available for helping smokers quit long-term (going at least six months without smoking). This is closely followed by using two forms of nicotine replacement therapy at the same time, such as a nicotine patch alongside gum, lozenges or nasal sprays.
An Update to the Overview of Reviews: Risks of and From SARS-COV-2 Infection and COVID-19 in People With Diabetes
Diabetes CareJamie Hartmann-Boyce et al
2023-12-01
"In 2020, we were commissioned by the World Health Organization (WHO) to conduct an overview of reviews regarding the extent to which people with diabetes are at increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or of suffering from its complications. We published this overview in Diabetes Care in 2021 (1). At the request of the WHO, we updated this review with literature through October 2022. Here, we provide readers with a summary of this update."
Treatment of Tobacco Smoking: A Review
JAMA NetworkNancy A. Rigotti, Gina R. Kruse, Jonathan Livingstone-Banks, Jamie Hartmann-Boyce
2022-02-08
"Approximately 34 million people in the US smoke cigarettes and could potentially gain up to a decade of life expectancy by stopping smoking. First-line therapy should include both pharmacotherapy and behavioral support, with varenicline or combination NRT as preferred initial interventions."
Social Media